FREE CASE EVALUATIONS AVAILABLE:
Gabriel F. Zambrano, P.A., is the sponsor of this website. As an advocate of the dangers and potential for injury from use of these pills, Gabriel F. Zambrano, P.A., continues to provide a FREE CASE EVALUATION for girls and women injured by the DRSP (drospirenone) family of pills.
The DRSP (DROSPIRENONE) family of birth control pills have drawn the attention of the FDA (Food & Drug Administration) by way of Four (4) FDA Warning Letters and a little publicized 'recall' in November 2009. Most recently, on September 26, 2011, as part of an ongoing evaluation available safety data, and emerging scientific evidence, the FDA announced that it remains concerned over the potential that DRSP (DROSPIRENONE) pills increase the risk of a blood clot, or related adverse event(s). Exactly how much these pills increase such risks is the subject of ongoing investigations, as well as pending lawsuits. Regardless, the FDA has announced that it is convening an advisory panel to hold public hearings during December 2011 to discuss conflicting data and related science.
The DRSP (DROSPIRENONE) family of birth control pills have drawn the attention of the FDA (Food & Drug Administration) by way of Four (4) FDA Warning Letters and a little publicized 'recall' in November 2009. Most recently, on September 26, 2011, as part of an ongoing evaluation available safety data, and emerging scientific evidence, the FDA announced that it remains concerned over the potential that DRSP (DROSPIRENONE) pills increase the risk of a blood clot, or related adverse event(s). Exactly how much these pills increase such risks is the subject of ongoing investigations, as well as pending lawsuits. Regardless, the FDA has announced that it is convening an advisory panel to hold public hearings during December 2011 to discuss conflicting data and related science.